Navigation Links
FDA Mandates New Warnings for Botox
Date:4/30/2009

Injection to relax muscle spasms carries severe risks, agency says,,

THURSDAY, April 30 (HealthDay News) -- Reports of deaths among people using popular anti-wrinkle injections such as Botox to treat muscle spasms have prompted a change in labeling.

Botox and similar products will now be required to carry boxed warnings, the most serious type of label warning, the U.S. Food and Drug Administration announced Thursday.

Most cases involved children given the drug to control muscle spasticity associated with cerebral palsy and adults using it to treat muscle spasticity, migraines and cervical dystonia.

"The hospitalizations are very few, deaths are very rare, but they have been reported," said Dr. Ellis F. Unger, acting deputy director of the FDA's Office of Drug Evaluation, said during a teleconference.

"We don't want to discourage use of these drugs as patients taking them have significant disability and the drugs are effective to relieve important problems," he said. "But people just need to understand the risks that are involved so they can make informed, risk-benefit decisions."

Other side effects include muscle weakness, difficulty breathing, loss of bladder control and pneumonia. Some people have required feeding tubes.

Unger said the deaths have not been clearly attributable to injection of the drugs, as everyone who died also suffered from other conditions.

None of the cases so far reported have been associated with use of botulinum products in cosmetic or dermatological procedures, such as clearing furrows between the eyebrows, according to the FDA. Botulinum toxins are not approved by the FDA to treat severe arm and leg muscle spasms, although they are approved for dermatological indications as well as cervical dystonia.

Officials believe that most of the problems occurred when one product was substituted for another without corresponding dose adjustments.

"There are now three products approved in the U.S., each with different units, and the units cannot be interchanged," Unger said. "Switching patients from one to another runs the risk of underdosing or, more important, overdosing."

The three approved products are Botox, Myobloc and Dysport, which was approved this week. Officials said there have been no post-marketing reports of similar problems with the newest drug.

The injections, which temporarily "paralyze" muscles, are intended to have a localized effect but can pose problems if the compound spreads to other parts of the body.

"When given in a particular place, they spread locally, meaning they move into adjacent structures," Unger explained. "We have known that for years, and it can be annoying and somewhat of a significant problem for given patients but does not result in disability or harm."

"The real concern is when there is distant spread," he said. "It is injected at one point and spreads to areas not adjacent."

The FDA issued an "early communication" in February 2008, warning of these adverse reactions. The month before, the watchdog group Public Citizen petitioned the agency to add a black-box warning to the two drugs then on the market in the United States, describing 180 "adverse event cases" related to the drugs, including 16 deaths, four in people younger than 18.

Between early 2008 and now, the FDA became "more certain about the cases," Unger said. "We felt we really needed to nail down the scope of the problem before we placed a boxed warning, which is something we take very seriously."

The FDA will also require manufacturers to put in place what it calls a risk evaluation and mitigation strategy -- in essence, a comprehensive patient safety guide.

"Updating labeling will help patients and health-care professionals better understand the risks and benefits," Unger said. "These drugs have benefits, but they also can cause serious problems."

More information

The American Academy of Dermatology has more on botulinum toxin products.



SOURCE: April 30, 2009, teleconference with Ellis F. Unger, M.D., acting deputy director, Office of Drug Evaluation I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Refuting Misconceptions About Health Insurance Mandates
2. Economic Stimulus Bill Mandates Electronic Health Records for Every American by 2014 - With No Opt-out Provision
3. Economic Stimulus Bill Mandates Electronic Health Records for Every Citizen without Opt-out or Patient Consent Provisions
4. FDA Mandates Black Box Warning for Some Antibiotics
5. Most Companies Oppose Single-Payer Health Care System, State Coverage Mandates
6. CAHI Releases Updated Health Insurance Mandates in the States
7. New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees
8. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
9. FDA Adds New Label Warnings to Over-the-Counter Painkillers
10. Docs Override Most Electronic Drug Warnings
11. TransMedia Group Retained by Renowned Plastic Surgeon Dr. Jeffrey Lagrasso to Share Beauty Trends, Warnings and Medical Perspective Previously Limited to the Rich and Famous
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Mandates New Warnings for Botox
(Date:1/20/2017)... , ... January 20, 2017 , ... “The Angel”: ... Lord has set out for each of his children. “The Angel” is the creation ... of Music in New York City, and impassioned writer. , When asked of her ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... January 20, 2017 , ... “God's Miracle Man: Against ... Odds” is the creation of published author, Keith C. A. Tucker, son of Minister ... Fellowship World Outreach pastured by Reverend Mark Hardy , “While sitting up in bed, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located in ... the growing demand of physicians and patients throughout the United States for high-quality ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 The global immunomodulators market ... 2025, according to a new study by Grand ... be predominantly driven by high R&D investments employed ... production of new and therapeutically advanced drugs. This ... at an unprecedented rate into the immunomodulators market ...
(Date:1/19/2017)... Jan. 19, 2017 The Global Therapy Partnering ... access to partnering deals and agreements entered into by ... partnering deals - Top deals by value - Deals ... technology type The report provides understanding and access ... the world,s leading healthcare companies. The report provides ...
(Date:1/19/2017)... 19, 2017 Conference Call and Webcast to Follow ... announced it will release results for the fourth quarter of 2016 ... ... conference call at 4:30 PM ET on Wednesday, February 15, 2017, ... 2016 financial results and other corporate activities. To participate in the ...
Breaking Medicine Technology: